EUVIMEDEUVIMED entdecken
Crossref

Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss

Ying-Nan Tsai iD, Jia-Ling Wu, Cheng-Hao Tseng iD, Tzu-Haw Chen, Ying-Chu Chung, Mindie H Nguyen iD, Jaw-Town Lin, Katsuya Nagaoka, Yasuhito Tanaka iD, Yao-Chun Hsu iD

Alimentary Pharmacology & Therapeutics · 2026-07 · 64 (1) · 89-102

DOI: 10.1111/apt.70658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 07.04.2026. Verfasst von Ying-Nan Tsai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Antiviral Agents, Hepatitis B, Chronic, Hepatitis B Core Antigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: E-Da Hospital, Tomorrow Medical Foundation, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulatory HBsAg and HBcrAg levels may fluctuate after nucleos(t)ide analogue (NA) withdrawal.

Aims

We aimed to characterize their dynamics and evaluate their performance in predicting clinical flares (CF) and HBsAg loss.

Methods

Non‐cirrhotic patients with chronic hepatitis B discontinuing NA according to Asia‐Pacific criteria were enrolled. CF was defined as ALT elevation > 5 times upper limit of normal following viral relapse. Circulatory HBsAg and HBcrAg levels were quantified using iTACT assays at treatment cessation and every 6 months thereafter until retreatment (up to 3 years). Predictive performance was evaluated using time‐dependent models.

Results

Of the 206 patients (median age, 50.0 years; 78.6% male) with a median treatment duration of 37.6 months (47.6% on entecavir), 68 experienced a CF (median follow‐up, 36.1 months) and 30 achieved HBsAg loss (median follow‐up, 70.3 months). Both HBcrAg and HBsAg decreased over time in patients with favourable outcomes (absence of CF or achievement of HBsAg loss). HBcrAg significantly outperformed HBsAg in predicting CF, with higher time‐dependent AUROCs (69.7%–71.3% vs. 57.8%–65.2%). Multivariable analyses confirmed that HBcrAg dynamics predicted CF more accurately (adjusted sub‐distribution hazard ratio [aSHR], 1.71 per log U/mL; 95% CI, 1.48–1.98), whereas HBsAg dynamics were superior in predicting HBsAg loss, with lower levels indicating a higher likelihood of clearance (aSHR, 0.33 per log IU/mL; 95% CI, 0.23–0.47).

Conclusions

HBcrAg dynamics more accurately predict CF, while HBsAg dynamics better predict HBsAg loss after NA cessation, supporting their complementary roles in clinical practice and suggesting distinct biological mechanisms underlying their production.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Surface AntigensAntiviral AgentsHepatitis B, ChronicHepatitis B Core AntigensHumansMaleFemaleMiddle AgedAdultGuaninePredictive Value of Tests

Stichwörter der Autor:innen

acute hepatitis flaresantiviral therapyfinite treatmenthepatitis b virusiTACT assays

Substanzen

Hepatitis B Surface AntigensAntiviral AgentsHepatitis B Core AntigensentecavirGuanine

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
  • School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
  • Department of Medical Research, E-Da Hospital, Kaohsiung, Taiwan.
  • Division of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
  • Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
  • Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, California, USA.

ORCID-Profile: Ying-Nan Tsai, Cheng-Hao Tseng, Mindie H Nguyen, Yasuhito Tanaka, Yao-Chun Hsu

Förderung

  • E-Da Hospital
  • Tomorrow Medical Foundation
  • Japan Agency for Medical Research and Development

Zitieren

APA

Tsai, Y. N., Wu, J. L., Tseng, C. H., Chen, T. H., Chung, Y. C., Nguyen, M. H., Lin, J. T., Nagaoka, K., Tanaka, Y., & Hsu, Y. C. (2026). Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss. Alimentary Pharmacology & Therapeutics, 64(1), 89-102. https://doi.org/10.1111/apt.70658

Vancouver

Tsai YN, Wu JL, Tseng CH, Chen TH, Chung YC, Nguyen MH, et al. Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss. Alimentary Pharmacology & Therapeutics. 2026;64(1):89-102. doi:10.1111/apt.70658

BibTeX
@article{Tsai2026,
  author = {Tsai, Ying-Nan and Wu, Jia-Ling and Tseng, Cheng-Hao and Chen, Tzu-Haw and Chung, Ying-Chu and Nguyen, Mindie H and Lin, Jaw-Town and Nagaoka, Katsuya and Tanaka, Yasuhito and Hsu, Yao-Chun},
  title = {Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {1},
  pages = {89--102},
  doi = {10.1111/apt.70658}
}
Kostenlos starten →